ASSERTIO HOLDINGS INC (ASRT)
US04546C2052 - Common Stock
Taking everything into account, ASRT scores 3 out of 10 in our fundamental rating. ASRT was compared to 193 industry peers in the Pharmaceuticals industry. While ASRT seems to be doing ok healthwise, there are quite some concerns on its profitability. ASRT is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
ASRT had negative earnings in the past year.
In the past year ASRT had a positive cash flow from operations.
In the past 5 years ASRT reported 4 times negative net income.
Of the past 5 years ASRT 4 years had a positive operating cash flow.
1.2 Ratios
ASRT has a Return On Assets of -24.81%. This is comparable to the rest of the industry: ASRT outperforms 59.47% of its industry peers.
ASRT's Return On Equity of -52.47% is in line compared to the rest of the industry. ASRT outperforms 55.79% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -24.81% | ||
| ROE | -52.47% | ||
| ROIC | N/A |
ROA(3y)-29.94%
ROA(5y)-28.06%
ROE(3y)-64.41%
ROE(5y)-123.67%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
In the last couple of years the Operating Margin of ASRT has declined.
Looking at the Gross Margin, with a value of 70.31%, ASRT is in the better half of the industry, outperforming 75.26% of the companies in the same industry.
In the last couple of years the Gross Margin of ASRT has declined.
The Profit Margin and Operating Margin are not available for ASRT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 70.31% |
OM growth 3YN/A
OM growth 5Y-12.55%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y-2.65%
2. Health
2.1 Basic Checks
ASRT does not have a ROIC to compare to the WACC, probably because it is not profitable.
ASRT has more shares outstanding than it did 1 year ago.
ASRT has more shares outstanding than it did 5 years ago.
ASRT has a better debt/assets ratio than last year.
2.2 Solvency
ASRT has an Altman-Z score of -2.36. This is a bad value and indicates that ASRT is not financially healthy and even has some risk of bankruptcy.
ASRT's Altman-Z score of -2.36 is in line compared to the rest of the industry. ASRT outperforms 43.68% of its industry peers.
The Debt to FCF ratio of ASRT is 1.91, which is an excellent value as it means it would take ASRT, only 1.91 years of fcf income to pay off all of its debts.
ASRT has a better Debt to FCF ratio (1.91) than 94.74% of its industry peers.
ASRT has a Debt/Equity ratio of 0.30. This is a healthy value indicating a solid balance between debt and equity.
ASRT's Debt to Equity ratio of 0.30 is in line compared to the rest of the industry. ASRT outperforms 40.53% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.3 | ||
| Debt/FCF | 1.91 | ||
| Altman-Z | -2.36 |
ROIC/WACCN/A
WACC9.76%
2.3 Liquidity
ASRT has a Current Ratio of 2.01. This indicates that ASRT is financially healthy and has no problem in meeting its short term obligations.
ASRT has a Current ratio (2.01) which is comparable to the rest of the industry.
A Quick Ratio of 1.57 indicates that ASRT should not have too much problems paying its short term obligations.
Looking at the Quick ratio, with a value of 1.57, ASRT is doing worse than 63.16% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.01 | ||
| Quick Ratio | 1.57 |
3. Growth
3.1 Past
ASRT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -177.66%.
The Revenue for ASRT has decreased by -25.80% in the past year. This is quite bad
Measured over the past years, ASRT shows a very negative growth in Revenue. The Revenue has been decreasing by -13.38% on average per year.
EPS 1Y (TTM)-177.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.48%
Revenue 1Y (TTM)-25.8%
Revenue growth 3Y12.68%
Revenue growth 5Y-13.38%
Sales Q2Q%-18.03%
3.2 Future
The Earnings Per Share is expected to grow by 21.95% on average over the next years. This is a very strong growth
The Revenue is expected to decrease by -0.40% on average over the next years.
EPS Next Y84.04%
EPS Next 2Y38.9%
EPS Next 3Y29.1%
EPS Next 5Y21.95%
Revenue Next Year-20.57%
Revenue Next 2Y-10.06%
Revenue Next 3Y-3.03%
Revenue Next 5Y-0.4%
3.3 Evolution
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ASRT. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ASRT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, ASRT is valued cheaply inside the industry as 97.89% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 4.07 | ||
| EV/EBITDA | -2.08 |
4.3 Compensation for Growth
ASRT's earnings are expected to grow with 29.10% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y38.9%
EPS Next 3Y29.1%
5. Dividend
5.1 Amount
ASRT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ASSERTIO HOLDINGS INC
NASDAQ:ASRT (12/23/2024, 12:26:32 PM)
0.867
-0.02 (-2.58%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners38.74%
Inst Owner Change-17.14%
Ins Owners0.95%
Ins Owner Change2.99%
Market Cap82.78M
Analysts82
Price Target3.09 (256.4%)
Short Float %5.96%
Short Ratio7.08
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)6.76%
Min EPS beat(2)-22.55%
Max EPS beat(2)36.06%
EPS beat(4)1
Avg EPS beat(4)-735.02%
Min EPS beat(4)-2890.2%
Max EPS beat(4)36.06%
EPS beat(8)2
Avg EPS beat(8)-454.84%
EPS beat(12)5
Avg EPS beat(12)-284.68%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.31%
Min Revenue beat(2)-0.83%
Max Revenue beat(2)1.44%
Revenue beat(4)2
Avg Revenue beat(4)1.01%
Min Revenue beat(4)-4.36%
Max Revenue beat(4)7.79%
Revenue beat(8)5
Avg Revenue beat(8)-1.38%
Revenue beat(12)9
Avg Revenue beat(12)1.54%
Revenue beat(16)13
Avg Revenue beat(16)3.1%
PT rev (1m)-3.81%
PT rev (3m)-3.81%
EPS NQ rev (1m)2.22%
EPS NQ rev (3m)-46.67%
EPS NY rev (1m)13.19%
EPS NY rev (3m)12.22%
Revenue NQ rev (1m)1.11%
Revenue NQ rev (3m)-2.51%
Revenue NY rev (1m)-0.23%
Revenue NY rev (3m)-0.23%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 0.66 | ||
| P/FCF | 4.07 | ||
| P/OCF | 4.03 | ||
| P/B | 0.63 | ||
| P/tB | 2.17 | ||
| EV/EBITDA | -2.08 |
EPS(TTM)-0.73
EYN/A
EPS(NY)-0.07
Fwd EYN/A
FCF(TTM)0.21
FCFY24.54%
OCF(TTM)0.22
OCFY24.84%
SpS1.32
BVpS1.37
TBVpS0.4
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -24.81% | ||
| ROE | -52.47% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 70.31% | ||
| FCFM | 16.16% |
ROA(3y)-29.94%
ROA(5y)-28.06%
ROE(3y)-64.41%
ROE(5y)-123.67%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)10.87%
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5Y-12.55%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y-2.65%
F-Score5
Asset Turnover0.46
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.3 | ||
| Debt/FCF | 1.91 | ||
| Debt/EBITDA | 5.13 | ||
| Cap/Depr | 1.03% | ||
| Cap/Sales | 0.2% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | 271.58% | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.01 | ||
| Quick Ratio | 1.57 | ||
| Altman-Z | -2.36 |
F-Score5
WACC9.76%
ROIC/WACCN/A
Cap/Depr(3y)16.92%
Cap/Depr(5y)10.44%
Cap/Sales(3y)3.59%
Cap/Sales(5y)2.28%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-177.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%93.48%
EPS Next Y84.04%
EPS Next 2Y38.9%
EPS Next 3Y29.1%
EPS Next 5Y21.95%
Revenue 1Y (TTM)-25.8%
Revenue growth 3Y12.68%
Revenue growth 5Y-13.38%
Sales Q2Q%-18.03%
Revenue Next Year-20.57%
Revenue Next 2Y-10.06%
Revenue Next 3Y-3.03%
Revenue Next 5Y-0.4%
EBIT growth 1Y-136.45%
EBIT growth 3YN/A
EBIT growth 5Y-24.25%
EBIT Next Year110.69%
EBIT Next 3Y30.79%
EBIT Next 5Y18.66%
FCF growth 1Y-63.65%
FCF growth 3YN/A
FCF growth 5Y-6.24%
OCF growth 1Y-63.28%
OCF growth 3YN/A
OCF growth 5Y-7.31%